×
0.0128179043743642 0.0128179043743642 0.0101729399796541 0.0101729399796541 0.0212614445574771 0.0328585961342829 0.0328585961342829 0.0222787385554426
Stockreport

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

ARGENX SE ADS (ARGX)  More Company Research Source: GlobeNewswire
PDF       -          Subcutaneous formulation offers potential for increased patient convenience and acceptance -   June 14, 2018 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced results from its Phase 1 clinical trial evaluating a subcutaneous (SC) formulation of efgartigimod (ARGX-113) in healthy volunteers. The data show that at the same dose level the SC formulation was comparable across key measures, including half-life, pharmacodynamics and tolerability, to the intravenous (IV) formulation used in clinical studies to date. argenx intends to use the data from the Phase 1 study to further explore SC dosing schedules of efgartigimod as a more convenient administration option for patients, including the potential of a loading dose of IV efgartigimod followed by SC m [Read more]

IMPACT SNAPSHOT EVENT TIME: ARGX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ARGX alerts

from News Quantified
Opt-in for
ARGX alerts

from News Quantified